anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Laminitis is a pathology of the equine digit ultimately leading to a failure of the dermo-epidermal interface. Neutrophil activation is recognized as a major factor in SIRS-associated laminitis and has recently been described in induced endocrinopathic laminitis evidenced by the presence of myeloperoxidase (MPO). Neutrophil extracellular traps (NET) are released with neutrophil activation. This study aimed to investigate the presence and activity of MPO and NET in the lamellar tissue of equids presented with naturally occurring laminitis. Samples of lamellar tissue of five horses and five donkeys presented with laminitis, as well as eight control horses without laminitis, were collected. Lamellar tissue extracts were submitted to ELISA and specific immuno-extraction followed by enzymatic detection (SIEFED) assays to confirm the presence and activity of both MPO and NET. Lamellar sections were also immunohistopathologically stained for MPO and NET. Analysis of lamellar tissue extracts revealed that laminitis cases had significantly higher levels of total MPO concentration, MPO activity, and NET-bound MPO activity in comparison to control horses. Moreover, a strong correlation was identified between the activity of NET-bound MPO and the total MPO activity, which suggests that MPO activity partly originates from NET-bound MPO. Immunohistochemical staining showed that MPO and NET labelling in laminitis cases was moderate to marked, primarily in the epidermis and in inflammatory infiltrates containing neutrophils, while labelling in control horses was minimal. This article constitutes the first indication of the presence and activity of NET-bound MPO in the lamellar tissue of horses and donkeys with naturally occurring laminitis. Targeting these substances may provide new treatment possibilities for this debilitating disease.
The recommended dose of carmustine for injection as a single agent in previously untreated patients is 150 to 200 mg/m2 intravenously every 6 weeks. Administer as a single dose or divided into daily injections such as 75 to 100 mg/m2 on two successive days. Lower the dose when carmustine for injection is used with other myelosuppressive drugs or in patients in whom bone marrow reserve is depleted. Administer carmustine for injection for the duration according to the established regimen. Premedicate each dose with anti-emetics.  
  
Adjust doses subsequent to the initial dose according to the hematologic response of the patient to the preceding dose. The following schedule is suggested as a guide to dosage adjustment:

  
  
  


The hematologic toxicity can be delayed and cumulative. Monitor blood counts weekly. Do not administer a repeat course of carmustine for injection until circulating blood elements have returned to acceptable levels (platelets above 100 Gi/L, leukocytes above 4 Gi/L and absolute neutrophil count above 1 Gi/L). The usual interval between courses is 6 weeks.

Evaluate renal function prior to administration and periodically during treatment. For patients with compromised renal function, monitor for toxicity more frequently. Discontinue carmustine for injection if the creatinine clearance is less than 10 mL/min. Do not administer carmustine for injection to patients with compromised renal function. Monitor transaminases and bilirubin periodically during treatment. [see Adverse Reactions (6)].
<P>PROBLEM TO BE SOLVED: To reduce the burden of cost by reducing the total stock while a pharmacy misses the chance of selling and to perform sure inventory management by eliminating inconsistency between the total stock on a computer and the actual total stock.  <P>SOLUTION: Medicines delivered from a medicine wholesaler 30 to a pharmacy 10 are not delivered as a stock of the pharmacy but are delivered to a stock space (called a backyard) of the medicine wholesaler, which is preliminarily preserved in the pharmacy. When a person in charge of the pharmacy 10 takes out medicines from the backyard, he or she reads a bar code stuck to a package of the medicines by a PDA or a bar code reader and checks them. Read data is transferred to a client terminal 12. At this time, the medicines become a store stock of the pharmacy. The client terminal 12 automatically prints a delivery slip for exclusive use and a receipt (B22-2).  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The invention discloses a nucleic acid aptamer specifically binding to TGEV S protein, wherein the nucleic acid aptamer sequence comprises at least one of the following four nucleotide sequences: A. a DNA sequence shown as SEQ ID No. 1; B. a DNA sequence having more than 60% homology with the DNA sequence shown in SEQ ID No. 1; C. a DNA sequence which hybridizes under stringent conditions to the DNA sequence shown in SEQ ID No. 1; D. an RNA sequence transcribed from the DNA sequence shown in SEQ ID No. 1; wherein, each of the four nucleotide sequences can specifically bind to TGEV S protein. The invention also discloses a nucleic acid aptamer derivative. The invention also discloses application of the nucleic acid aptamer or the nucleic acid aptamer derivative. The invention can be combined with TGEV S protein specifically, has stable chemical property and is easy to store and mark.
The incidence of anesthesia awareness (AA) is 0.1-0.2% and may result in post traumatic stress disorders. For some patients, owing to illness, medications, substance misuse or surgery, the risk approaches 1%. The B-AWARE Study by Myles et al. suggested that the bispectral index (BIS) monitor, which reportedly reflects anesthetic depth, may decrease the incidence of AA in higher risk patients by 82%. The American Society of Anesthesiologists has published a practice advisory on AA, which does not recommend the routine use of cerebral function monitors. We propose to test the hypothesis that an anesthetic protocol based on BIS decreases the incidence of AA among higher risk patients compared with an anesthetic protocol based on the end-tidal anesthetic gas (ETAG) concentration. We have completed a randomized, single-blinded prospective feasibility study (The B-Unaware Trial) which enrolled 2000 patients at higher risk for AA. Four patients (0.21%; 95% CI=0.06% to 0.57%) had definite AA, of whom two were in the BIS-guided group and two in the ETAG-guided group. Nine patients (0.46%; 95% CI=0.22% to 0.91%) had definite or possible AA, of whom six were in the BIS-guided group and three in the ETAG-guided group. The BAG RECALL study will be a multi-center, prospective, single-blinded, randomized study enrolling 6000 patients at higher risk for AA. The BAG RECALL study is adequately powered and rigorously designed to answer with a reasonable degree of scientific probability whether BIS guidance results in clinically relevant reduction in anesthesia awareness among higher risk patients undergoing general anesthesia.

At the University of Michigan, a parallel study will be conducted - Michigan Awareness Control Study, MACS (NCT00689091) - enrolling 30,000 patients to assess whether the BIS monitor decreases the likelihood of anesthesia awareness among all patients undergoing general anesthesia, regardless of their risk profile. The investigators of this study and the BAG-RECALL study have collaborated in designing these studies and are pre-specifying that common outcome measures will be examined collaboratively including data from both studies.
Vitamin concentrates or synthetically produced vitamins are incorporated in carbonic acid-evolving compositions of the type containing substances of acid reaction such as tartaric or citric acids or acid sodium phosphate in conjunction with one or more carbonates, for example, sodium bicarbonate.  The vitamin concentrate in powder form may be added to a mixture of the other constituents, but preferably it is first mixed with part or all of the acidic constituent.  Thus, the vitamin concentrate may be added to a solution of the acid substance which is evaporated to dryness.  Or an alcoholic solution of the vitamin may be mixed with acid, a small quantity of water added, and the mixture evaporated to dryness.  In an example, a vitamin-containing fruit extract in alcoholic solution is added to tartaric acid, evaporated to a semi-fluid mass, and desiccated under reduced pressure at 40 DEG  C. whilst being stirred. Evaporation is carried out in the presence of an indifferent gas such as carbon dioxide or nitrogen.  Mixing of the product with the other constituent may also be effected in an indifferent atmosphere, and the preparation may be stored in such an atmosphere.  The vitamin is protected against decomposition by the acid, and also by the carbon dioxide atmosphere.ALSO:Vitamin concentrates or synthetically produced vitamins are incorporated in carbonic acid-evolving compositions of the type containing substances of acid reaction such as tartaric or citric acids or acid sodium phosphate in conjunction with one or more carbonates, for example, sodium bicarbonate.  The vitamin concentrate in powder form may be added to a mixture of the other constituents, but preferably it is first mixed with part or all of the acidic constituent.  Thus, the vitamin concentrate mass be added to a solution of the acid substance which is evaporated to dryness.  Or an alcoholic solution of the vitamin may be mixed with acid, a small quantity of water added, and the mixture evaporated to dryness.  In an example, a vitamin-containing fruit extract in alcoholic solution is added to tartaric acid, evaporated to a semi-fluid mass, and desiccated under reduced pressure at 40 DEG  C. whilst being stirred.  Evaporation is carried out in the presence of an indifferent gas such as carbon dioxide or nitrogen.  Mixing of the product with the other constituent may also be effected in an indifferent atmosphere, and the preparation may be stored in such an atmosphere.  The vitamin is protected against decomposition by the acid, and also by the carbon dioxide atmosphere.
The invention relates to the field of daily cosmetics, and in particular relates to a hair conditioner containing Chinese medicinal hemp seed oil and oily components of fructus viticis and eupatorium serving as matrix or nutrient additives and a preparation method of the hair conditioner. The hemp seed oil and the oily components of the fructus viticis and the eupatorium can be extracted by a solvent method or other methods (such as a squeezing method or a water vapor distillation method). The oily components of the three are combined into hemp seed compound essential oil for preparing the hair conditioner. The hair conditioner comprises the following components: 4 to 10 percent of hemp seed compound essential oil, 2 to 6 percent of a cation surfactant, 3 to 7 percent of fat excipient, 2 to 3 percent of a wetting agent, 0.05 to 0.1 percent of a chelating agent, 0.3 to 0.6 percent of a preservative, and the balance of water. The hair conditioner has the effects of improving the nutrition of hair follicles, eliminating scalp allergy and preventing alopecia, and can improve the hair quality, protect the surface of hair, repair injury such as hair yellowness, branching and easy breakage caused by various factors and achieve the effects of hairdressing, protecting the hair and treating both symptoms and root causes. By insisting on using the hair conditioner, hair can be grown and beautified, and the hair is black, glossy, smooth as silk and easy to comb.
Women receive the standard of care Quit Smoking Now tobacco education and support only. Smoking status will be monitored from quit date through 3 months postpartum via carbon monoxide and salivary cotinine levels. Incentives are given for providing breath and salivary samples but are not contingent on smoking status.
An automated kiosk is located adjacent to a point of access to a room or premises. The kiosk can control an automated locking mechanism for the point of access. The kiosk can read the temperature of all persons that attempt to enter the room or premises. The kiosk can also command the persons to sanitize their hands in a sanitation window of the kiosk while dispensing sanitizer and monitoring the hands of the person for effective sanitation action. The kiosk can read identification credentials, perform facial recognition, speech recognition and recognize gestures of persons. The kiosk can be further coupled to a central control computer.
The study uses a mixed factorial design with one between subject factor (OPRM1 genotype_: Asn40/Asn40 vs. Asn40/Asp40 or Asp40/Asp40) and one within-subject factor (IV nicotine vs. IV saline) to examine genotype by nicotine interactions on MOR binding potential (BP_ND ) assessed via PET imaging with \[11 C\]carfentanil. Twenty-four smokers (12 male, 12 female; 12 from each genotype group) will participate in two 90 minute PET sessions following overnight (14-hours) abstinence from nicotine. Genotype groups will be matched for age and sex . One week prior to the first PET session, there will be an adaptation session during which participants will receive IV saline followed 30 minutes later by IV nicotine (1 mg/70 kg) to ensure that they tolerate the procedure. In the PET sessions, participants will receive either IV nicotine (1 mg/70 kg) or saline (within-subject, double blind, counterbalanced). The primary outcomes will be BP_ND in ventral striatum and anterior cingulate cortex (ACC). Normally menstruating women will be scheduled for their sessions during the early follicular phase. Sessions will be separated by 1 month for all participants to reduce variability in MOR binding due to hormonal changes during females menstrual cycles. Participants will complete subjective measures of nicotine reward and craving at each session.
In the main study, participants will receive apalutamide 240 milligram (mg) once daily orally along with ADT for 12 cycles (Each cycle is of 28 days). Participants who enrolled in the sub-study will receive apalutamide 240 mg once daily along with relugolix (a type of ADT) 120 mg once daily following a loading dose of 360 mg relugolix orally. Sub-study participants will be receiving relugolix up to Day 28 after which they will be transitioned into the main study from Cycle 2 Day 1 and will continue to receive conventional or oral ADT.
The invention discloses a docetaxel freeze-dried microemulsion preparation and a preparation method thereof. The docetaxel freeze-dried microemulsion preparation comprises the following raw materials by weight: 0.05-5 parts of docetaxel, 0.1-40 parts of an oil phase, 5-30 parts of a surfactant, 0-40 parts of a cosurfactant, 5-85 parts of a hydrophilic phase, 0-15 parts of a cosolvent, 0-5 parts of an antioxidant, and 1-40 parts of a freeze-drying protective agent. Specifically, the surfactant is one or several of polyethylene glycol-8-caprylin/caprin, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, poloxamer, polyethylene glycol-12-hydroxystearate, polyethylene glycol stearate 15 and sorbitan monooleate. The preparation method includes: preparing the raw materials into a microemulsion according to the ratio, and then conducting freeze-drying. Before clinical use, the docetaxel freeze-dried microemulsion preparation has no need for a tedious two-step dilution process, after redissolving, the docetaxel freeze-dried microemulsion preparation can be subjected to intravenous injection, and has no vascular irritation and small allergic reaction. Hemolytic experiments show that the docetaxel freeze-dried microemulsion preparation does not generate hemolysis.
In the last few years, a marked decrease in the quality of semen has been reported. Infertility is one of the major health problems in 10 to 15% of couples' lives; from which approximately 50% of couple's infertility is due to Male factors. The aim of the present study was to evaluate an herbal mixed effects on spermatogenesis and the normal production of sperm. Researchers have reported that using antioxidants and vitamins A, B, C, E, flavonoids, Sulfur compounds, terpenoids and phenolic compounds in the daily diet can protect sperm. In this study the investigators aimed to assess synergistic effect of these herbal compounds in male Infertility. 700 mg tablet for 180 consequence days/daily will be advising, for 40 patients semen samples in 1th and 180 day after treatment will take, in andrology lab according WHO method:samples put into 2 mL of medium (Hams F10) containing 0.5% bovine serum albumin. After 5 min incubation at 37oC (with 5% CO), the sperm samples were determined using the standard haemocytometric method, and sperm motility was analyzed by microscope (Olympus IX70) at 10 field and reported as the mean of motile sperm according to WHO methods . The sperm abnormality was evaluated according to the standard method of Narayana .Briefly, smears of the sperm suspension were made on clean glass slides and stained with periodic acid-Schiff's reaction haematoxylin. The stained smears were observed under a light microscopic with 40× magnification. The sperms were classified into normal and abnormal. The total sperm abnormality was expressed as percentage incidence. Other biochemical tests will be doing according the our research protocol and thesis for blood samples for measure LH, Testosterone, TAC, Glc and Cholesterol.
BACKGROUND: The use of a self-adherent, elastic bandage is a practical way to dress finger injuries. Multiple reports describe iatrogenic injuries from elastic bandages, ranging from skin necrosis to finger gangrene, necessitating amputations. This study investigated whether elastic bandages can compromise digital perfusion by occluding arterial blood flow in healthy volunteers and evaluated the utility of pulse oximetry as a monitoring tool for digital perfusion. A technique for safe bandage application is proposed.
METHODS: A commercially available elastic bandage was wrapped around the index finger of 20 healthy volunteers at varying degrees of stretch. Digital perfusion measurements were carried out using photoelectric pulse transduction, laser Doppler flowmetry, and pulse oximetry. Intracompartmental pressure measurements were recorded using a separate in vitro experimental model.
RESULTS: Elastic bandages applied at maximum stretch did not change digital brachial index or pulse oximetry values, suggesting arterial blood flow was preserved distal to the bandage. Intracompartmental pressure measurements at maximum stretch remained below the systolic digital pressure. In contrast, superficial dermal perfusion fell to 32% of normal as measured by laser Doppler flow, at 100% bandage stretch.
CONCLUSION: This study suggests a risk for iatrogenic injury when using elastic bandages for finger dressings. While arterial inflow was never compromised, pressures were high enough to occlude superficial venous outflow, which may begin at 20% bandage stretch. Pulse oximetry failed to detect changes distal to applied dressings, and we do not recommend it to detect digital vascular compromise in this setting.
This study is prospective in nature. Subjects in the control group will be treated according to treatment as usual and best judgment of the treating physician. PEER Interactive Report is not provided to the investigator. The subjects will be followed for 6 months after the initial treatment, or until the patient has achieved maximum medical improvement (MMI). The patient will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health.
The invention relates to a method for preparing nerve growth factor(NGF) oral administered capsule. The invention adopts the capsule formulation instead of the injection. The method features in that NGF and adjuvant sodium dodecylsulfate, casein, microcrystalline cellulose are being mixed, stirred, placed under low temperature and freeze dried then be packed. Capsule prepared by the method have four times biological activity than that of NGF solution. The capsule is safe ,portable ,having no need of preservation under low temperature. At present, no same formulation exists in home and broad and is estimated to has a favorable prospect.
The present invention discloses a medicinal composition for treating depression or anxiety neurosis and a preparation method for the composition. The medicinal composition takes hypericum perforatum, curcuma root, grassleaf sweetflag rhizome, ginseng, thinleaf milkwort root and albizia flower as raw materials. The curcuma root and the grassleaf sweetflag rhizome are taken, volatile oil is extracted by a steam distillation method, and beta-cyclodextrin is used for clathration to obtain beta-cyclodextrin inclusion compounds. Aqueous extract liquid is concentrated, dried into dry paste after the oil is extracted. The hypericum perforatum and the ginseng are taken to be extracted in reflux by alcohol, and are concentrated and dried into dry paste. The thinleaf milkwort root and the albizia flower are in aqueous extract to be concentrated and dried into dry paste. The three kinds of dry paste are mixed with the beta-cyclodextrin inclusion compounds to be ground and sieved to prepare capsules of the present invention. The medicinal composition of the present invention can be used for treating depression or anxiety neurosis.
Specific plant extracts are applied topically to upregulate genes which code for proteins to prevent the build-up of and mitigate the activity of various harmful materials within the skin. These upregulated proteins include glutathione transferases, peroxiredoxins, oxidoreductases, glutaredoxins and glutathione syntheses. These proteins produce additional glutathione, glyoxalase I, maintain cellular redox homeostasis, reduce hydrogen peroxide and alkylhydroperoxides, and conjugate glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Keratinocytes have been induced to significantly upregulate glutathione and glyoxalase I protein expression. Additionally, keratinocytes pre-treated with diallyl trisulfide have increased viability when exposed to ozone, UV radiation or cigarette smoke extract. The active material can be extracted from plants such as garlic, onions, shallots, leeks, chives, scallions, brussel sprouts, broccoli, cabbage, cauliflower, bok choy, kale, mustard, turnip or radish, may include any compound of the allyl sulfide family, and may be of synthetic origin.